Sanofi to acquire Principia Biopharma

The late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases has entered into a definitive agreement with Sanofi

picture of

Breaking News

Novacyt signs contract to supply PCR instruments to UK DHSC

This is the second major contract awarded by the DHSC to Primerdesign, Novacyt’s molecular diagnostics division, ...

Sanofi completes Principia Biopharma acquisition

Principia Biopharma is now a wholly owned subsidiary of Sanofi

Thomas H. Lee Partners and Frazier Healthcare Partners acquire Adare

The transaction includes specialty CDMO business, including pharmaceutical technology and microbiome businesses

Royal Society of Chemistry calls for R&D investment

The UK has fallen behind cohort nations in R&D investment, hampering efforts to boost productivity – with the impact ...

Gilead acquires Immunomedics for $21bn

The transaction is anticipated to close during Q4 2020

Scenic Biotech enters into genetic modifier collaboration with Genentech

Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease ...

Beximco Pharma: The Bangladeshi company connecting with the US

COO Rabbur Reza talks about the strategy behind approaching pharmaceutical manufacturing from an emerging market

DCprime and Glycotope to advance cancer vaccination and therapeutic antibody platforms

DCprime, the front-runner in the field of relapse vaccines, and Glycotope GmbH, a clinical-stage oncology/immuno- ...

T-knife and Catalent Sign to collaborate on autologous T-cell receptor-based cell therapy

Under the terms of the agreement, Catalent will undertake transfer of T-knife´s platform process for T-cell receptor- ...

The experiment: human versus machine

In this article Miha Možina, PhD, Business Developer at Sensum discusses why he believes investment decisions should ...

Addressing the need for cost-effective vaccine manufacturing

Process intensification and integrated continuous bioprocessing are two approaches that can be used to achieve cost- ...

BioCity predicts proliferation of workspace amid life science ventures boom

The UK's life science incubator has released the Life Science Start-Up Report with in-depth analysis of emerging ...

Inflazome announces acquisition by Roche

Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address ...

ERS Genomics signs deal with Applied StemCell

ERS Genomics holds an exclusive worldwide license from Dr Charpentier to the foundational patents covering CRISPR/Cas9